Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Cited by (1,003)

Items 901–1,000 of 1,003

1. Peptidomimetic-Based Vesicles Inhibit Amyloid-β Fibrillation and Attenuate Cytotoxicity
   Debabrata Maity, Madeline Howarth, Maria Chalokh Vogel, Mazin M. Magzoub, Andrew D. Hamilton · 2021 · Journal of the American Chemical Society
2. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Aβ1‐6 upregulates IL‐10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease
   Hong‐Duck Kim, Kazuki Tahara, J. Adam Maxwell, Robert Lalonde, Tatsuya Fukuiwa, Kohtaro Fujihashi, Kent R. Van Kampen, Fan-Kun Kong, De-chu Christopher Tang, Ken‐ichiro Fukuchi · 2007 · The Journal of Gene Medicine
3. Potential Treatment Opportunities for Alzheimer's Disease Through Inhibition of Secretases and Aβ Immunization
   Dale Schenk, Dora Games, Peter Seubert · 2001 · Journal of Molecular Neuroscience
4. Immunotherapy of Alzheimer's disease (AD): From murine models to anti-amyloid beta (Aβ) human monoclonal antibodies
   Valeria Geylis, Michael O Steinitz · 2005 · Autoimmunity Reviews
5. Alzheimer's vaccine: a cure as dangerous as the disease?
   Gerald W Münch, Stephen R. Robinson · 2002 · Journal of Neural Transmission
6. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice
   Peng Zhao, Yuanzhong Xu, Xuejun Fan, Leike Li, Xin Li, Hisashi Arase, Qingchun Tong, Ningyan Zhang, Zhiqiang An · 2022 · mAbs
7. Monoclonal Antibody Therapy in Alzheimer’s Disease
   Monica Neațu, Anca Covaliu, Iulia Ioniță, Ana Jugurt, Eugenia Irene Davidescu, Bogdan Ovidiu Popescu · 2023 · Pharmaceutics
8. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease
   Lakshman Puli, Yuriy Pomeshchik, Katja Olas, Tarja Malm, Jari Koıstınaho, Heikki Tanila · 2012 · Journal of Neuroinflammation
9. Intraventricular infusion of clusterin ameliorated cognition and pathology in Tg6799 model of Alzheimer’s disease
   Xue-Mei Qi, Cheng Wang, Xingkun Chu, Gen Li, Jianfang Ma · 2018 · BMC Neuroscience
10. Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production
    Mark A. Lovell, Erin L. Abner, Richard J. Kryscio, Liou Xu, Shuling X. Fister, Bert C. Lynn · 2015 · Oxidative Medicine and Cellular Longevity
11. Chapter 12 P2Y6‐Evoked Microglial Phagocytosis
    Kazuhide Inoue, Schuichi Koizumi, Ayako Kataoka, Hidetoshi Tozaki‐Saitoh, Makoto Tsuda · 2009 · International review of neurobiology
12. β -Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain A β Levels in APPswe/PS1ΔE9 Mice, as Detected by SELDI-TOF-Based ProteinChip ® Technology
    Anne K. Vehmas, David Borchelt, Donald L. Price, Diane B. McCarthy, Marsha A. Wills-Karp, Marilyn J. Peper, Gay L. Rudow, Jackie Luyinbazi, Lawrence T. Siew, Juan Carlos Troncoso · 2001 · DNA and Cell Biology
13. Vaccines for Alzheimer??s Disease
    Christopher Janus · 2003 · CNS Drugs
14. Anti‐amyloid activity of neprilysin in plaque‐bearing mouse models of Alzheimer's disease
    M. Hasan Mohajeri, Katrin Kuehnle, Hong Li, Raphaël Poirier, Jay Tracy, Roger M. Nitsch · 2004 · FEBS Letters
15. Effect of active A<i>β</i> immunotherapy on neurons in human Alzheimer's disease
    Paquet, Claire, Amin, Jay, Mouton‐Liger, François, Nasser, Mariam, Love, Seth, Gray, Françoise, Pickering, Ruth M, Nicoll, James AR, Holmes, Clive, Hugon, Jacques et al. · 2015 · The Journal of Pathology
16. Initiation and propagation of neurodegeneration
    Christian Haass · 2010 · Nature Medicine
17. Engineered antibody approaches for Alzheimer’s disease immunotherapy
    Remy Robert, Kim L. Wark · 2012 · Archives of Biochemistry and Biophysics
18. Glial reactions and the clearance of amyloid β protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type
    Marion L. C. Maat–Schieman, Haruyasu Yamaguchi, Ingrid M. Hegeman-Kleinn, Corrie Welling‐Graafland, Remco Natté, Raymund A.C. Roos, Sjoerd G. van Duinen · 2004 · Acta Neuropathologica
19. Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
    Rawan M. Tarawneh, David M. Holtzman · 2009 · CNS & Neurological Disorders - Drug Targets
20. Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
    Sandra Rocha · 2013 · Current Pharmaceutical Design
21. The past, present, and future of disease-modifying therapies for Alzheimer’s disease
    Kazushi Suzuki, Atsushi Iwata, Takeshi Iwatsubo · 2017 · Proceedings of the Japan Academy Series B
22. Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models
    Veronica Corsetti, Antonella Borreca, Valentina Latina, Giacomo Giacovazzo, Annabella Pignataro, Paraskevi Krashia, Francesca Natale, Sara Cocco, Marco Rinaudo, Francesca Malerba et al. · 2020 · Brain Communications
23. Untitled work
    2012 · PubMed
24. Therapeutic options in Alzheimer’s disease
    Paula Isabel Moreira, Xiongwei Zhu, Akihiko Nunomura, Mark A. Smith, George L. Perry · 2006 · Expert Review of Neurotherapeutics
25. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
    Rudy J. Castellani, Xiongwei Zhu, Hyoung‐gon Lee, Paula Isabel Moreira, George L. Perry, Mark A. Smith · 2007 · Expert Review of Neurotherapeutics
26. Blood-Brain Barrier Permeability Correlates with Medial Temporal Lobe Atrophy but Not with Amyloid-β Protein Transport across the Blood-Brain Barrier in Alzheimer’s Disease
    Yasuko Matsumoto, Daisuke Yanase, Moeko Noguchi‐Shinohara, Kenjiro Ono, Mitsuhiro Yoshita, Masahito Yamada · 2007 · Dementia and Geriatric Cognitive Disorders
27. Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial
    Tyler A. Kokjohn, Alex E. Roher · 2009 · CNS & Neurological Disorders - Drug Targets
28. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
    Jonathan K. Foster, Giuseppe Verdile, K A Bates, Ralph Nigel Martins · 2008 · Molecular Psychiatry
29. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
    Panza, Francesco, Seripa, Davide, Lozupone, Madia, Solfrizzi, Vincenzo, Imbimbo, Bruno P., Barulli, Maria Rosaria, Tortelli, Rosanna, Capozzo, Rosa, Bisceglia, Paola, Dimitri, Andrea et al. · 2018 · Expert Opinion on Biological Therapy
30. Receptor–mediated transcytosis of macromolecules across the blood–brain barrier
    Habib Baghirov · 2023 · Expert Opinion on Drug Delivery
31. Novel Transgenic Rice-Based Vaccines
    Tatsuhiko Azegami, Hiroshi Itoh, Hiroshi Kiyono, Yoshikazu Yuki · 2014 · Archivum Immunologiae et Therapiae Experimentalis
32. Progress in the development of new drugs in Alzheimer's disease
    Antoine Piau, Fati Nourhashémi, Christophe Hein, Céline Caillaud, Bruno J. Vellas · 2011 · The journal of nutrition health & aging
33. Intramuscular delivery of p75<scp>NTR</scp> ectodomain by an <scp>AAV</scp> vector attenuates cognitive deficits and Alzheimer's disease‐like pathologies in APP/<scp>PS</scp>1 transgenic mice
    Wang, Qing‐Hua, Wang, Ye‐Ran, Zhang, Tao, Jiao, Shu‐Sheng, Liu, Yu‐Hui, Zeng, Fan, Li, Jing, Yao, Xiu‐Qing, Zhou, Hua‐Dong, Zhou, Xin‐Fu et al. · 2016 · Journal of Neurochemistry
34. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
    Crystal M. Vander Zanden, Eva Y. Chi · 2019 · Journal of Pharmaceutical Sciences
35. The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy
    Pablo Cisternas, Xavier Taylor, Cristian A. Lasagna‐Reeves · 2019 · International Journal of Molecular Sciences
36. Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain
    Fadi Rofo, Canan Uğur Yılmaz, Nicole G. Metzendorf, Tobias Gustavsson, Chiara Beretta, Anna Erlandsson, Dag Sehlin, Stina Syvänen, Per Nilsson, Greta Hultqvist · 2020 · Theranostics
37. Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
    Jacqui Nimmo, Louise Kelly, Ajay Kumar Verma, Roxana Octavia Carare, James A. R. Nicoll, Jean‐Cosme Dodart · 2021 · Frontiers in Neuroscience
38. Behavioral effects of CD40–CD40L pathway disruption in aged PSAPP mice
    J. Todd Roach, Claude‐Henry Volmar, Samvid Dwivedi, Terrence Town, Robert M. Crescentini, Fiona Crawford, Jun Tan, MICHAEL J. MULLAN · 2004 · Brain Research
39. Antibody to β-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice
    Susan A. Farr, William A. Banks, Kayoko Uezu, Atsuko Sano, Frederich S. Gaskin, John Edward Morley · 2003 · Life Sciences
40. Heat shock protein-90-induced microglial clearance of exogenous amyloid-β1–42 in rat hippocampus in vivo
    Kazuyuki Takata, Yoshihisa Kitamura, Daiju Tsuchiya, Toshiyuki Kawasaki, Takashi Taniguchi, Shun Shimohama · 2003 · Neuroscience Letters
41. Vaccination with Aβ-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral Aβ and Lowers Plaque Burden in APP Transgenic Mice
    Patricia Bach, Jakob‐A. Tschäpe, Ferdinand Kopietz, Gundula Braun, Janina K. Baade, Karl‐Heinz Wiederhold, Matthias Staufenbiel, Marco Prinz, Thomas Deller, Ulrich Kalinke et al. · 2009 · The Journal of Immunology
42. Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease
    Guriqbal S. Basi, Hadar Feinberg, Farshid Oshidari, John Anderson, Robin Barbour, Jeanne Baker, Thomas A. Comery, Linnea Diep, Davinder S. Gill, Kelly Johnson‐Wood et al. · 2009 · Journal of Biological Chemistry
43. IgM-Dependent Phagocytosis in Microglia Is Mediated by Complement Receptor 3, Not Fcα/μ Receptor
    Jonathan R. Weinstein, Yi Quan, Josiah F. Hanson, Lucrezia Colonna, Michael Iorga, Shin-ichiro Honda, Kazuko Shibuya, Akira Shibuya, Keith B. Elkon, Thomas Möller · 2015 · The Journal of Immunology
44. Toward Alzheimer Therapies Based on Genetic Knowledge
    John Hardy · 2004 · Annual Review of Medicine
45. Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence
    Tracey A. Ignatowski, Robert N. Spengler, Krishnan M. Dhandapani, Hedy Folkersma, Roger F. Butterworth, Edward Lewis Tobinick · 2014 · CNS Drugs
46. Prevention of Alzheimer's disease
    Christine A. Szekely, John C.S. Breitner, Peter P. Zandi · 2007 · International Review of Psychiatry
47. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood–brain barrier
    Michaela Prinz, Sülünay Parlar, Gülşah Bayraktar, Vildan Alptüzün, Erçin Erciyas, Adyary Fallarero, Daniela Karlsson, Pia Maarit Vuorela, Małgorzata Burek, Carola Yvette Förster et al. · 2013 · European Journal of Pharmaceutical Sciences
48. Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen
    Roland Jakob‐Roetne, Helmut Jacobsen · 2009 · Angewandte Chemie
49. Invited review: Drug development for tauopathies
    Fiona Grüninger · 2014 · Neuropathology and Applied Neurobiology
50. Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials
    Delphine Boche, James A. R. Nicoll · 2020 · Neuropathology and Applied Neurobiology
51. Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease
    Kumpal Jagdish Madrasi, Raibatak Das, Hafiz Mohmmad Abdul, Lin Lin, Bradley T. Hyman, Douglas A. Lauffenburger, Mark W. Albers, Robert A. Rissman, John M. Burke, Joshua F. Apgar et al. · 2021 · Alzheimer s & Dementia
52. Roles of microglia in Alzheimer’s disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention
    Kazuyuki Takata, Florent Ginhoux, Shun Shimohama · 2021 · Biochemical Pharmacology
53. Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
    Yara Al Ojaimi, Timothée Blin, Juliette Lamamy, Matthieu Gracia, Aubin Pitiot, Caroline Denevault‐Sabourin, Nicolas Joubert, Jean‐Pierre Pouget, Valérie Gouilleux‐Gruart, Nathalie Heuzé‐Vourc'h et al. · 2021 · Pharmacology & Therapeutics
54. Therapeutic approaches for prion and Alzheimer's diseases
    Thomas Wısnıewskı, Einar M. Sigurdsson · 2007 · FEBS Journal
55. Immune response to Aβ-peptides in peripheral blood from patients with Alzheimer's disease and control subjects
    Laurence Baril, L. Sans de San Nicolàs, Bernard Croisile, Pierre Crozier, Catherine Hessler, Agnès Sassolas, Joseph B. McCormick, Emanuelle Trannoy · 2003 · Neuroscience Letters
56. Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease
    Hiroaki Taguchi, Stephanie A. Planque, Yasuhiro Nishiyama, Paul Szabo, Marc E. Weksler, Robert Paul Friedland, Sudhir Paul · 2008 · Autoimmunity Reviews
57. What is the dominant aβ species in human brain tissue? A review
    Gillian C. Gregory, Glenda Margaret Halliday · 2005 · Neurotoxicity Research
58. Interaction of Alzheimer’s Aβ Peptide with an Engineered Binding Protein—Thermodynamics and Kinetics of Coupled Folding–Binding
    Wolfgang Hoyer, Torleif Härd · 2008 · Journal of Molecular Biology
59. Drug Insight: emerging therapies for amyloidosis
    Julian David Gillmore, Philip Nigel Hawkins · 2006 · Nature Reviews Nephrology
60. New developments in animal models of Alzheimer’s disease
    Christopher Janus, Amie L. Phinney, Muhammad Azhar Chishti, David A. Westaway · 2001 · Current Neurology and Neuroscience Reports
61. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G)
    Marcel Maier, Timothy J. Seabrook, Cynthia Ann Lemere · 2005 · Vaccine
62. Amyloid β vaccination: reduced plaques and improved cognition
    Steven G. Younkin · 2001 · Nature Medicine
63. Alzheimer's Disease Modeling: Ups, Downs, and Perspectives for Human Induced Pluripotent Stem Cells
    Urszula Wojda, Jacek Kuźnicki · 2013 · Journal of Alzheimer s Disease
64. Natural Secretory Products of Human Neural and Microvessel Endothelial Cells: Implications in Pathogenic "Spreading" and Alzheimer's Disease
    Yuhai Zhao, Jian-Guo Cui, Walter J. Lukiw · 2006 · Molecular Neurobiology
65. Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
    Chaoyun Li, Azadeh Ebrahimi, Hermann J. Schluesener · 2012 · Ageing Research Reviews
66. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice
    Suhail Rasool, Ricardo Albay, Hilda Martínez‐Coria, Leonid Breydo, Jessica Wu, Saskia C. F. Milton, Sunit Misra, Andy T Tran, Anna Pensalfini, Frank M. LaFerla et al. · 2012 · Molecular Neurodegeneration
67. Aβ peptide conformation determines uptake and interleukin-1α expression by primary microglial cells
    Saravanapavan Parvathy, Jayakumar Rajadas, Heather S. Ryan, Sepideh Vaziri, Laurel Anderson, Greer M. Murphy · 2008 · Neurobiology of Aging
68. ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals
    Lara Ordóñez‐Gutiérrez, Adrián Posado-Fernández, Davoud Ahmadvand, Barbara Lettiero, Linping Wu, Marta Antón, Orfeu Flores, Seyed Moein Moghimi, Francisco G. Wandosell · 2016 · Biomaterials
69. Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity
    Erica M. Weekman, Tiffany L. Sudduth, Carly N. Caverly, Timothy Joseph Kopper, Oliver W. Phillips, Dave K. Powell, Donna M. Wilcock · 2016 · Journal of Neuroscience
70. The Effects of Soluble A.β Oligomers on Neurodegeneration in Alzheimer's Disease
    Jonathan Brouillette · 2014 · Current Pharmaceutical Design
71. Nanoliposomes as a Therapeutic Tool for Alzheimer’s Disease
    Lara Ordóñez‐Gutiérrez, Francisco G. Wandosell · 2020 · Frontiers in Synaptic Neuroscience
72. Regression stage senile plaques in the natural course of Alzheimer’s disease
    T. Oide, T. Kinoshita, K. Arima · 2006 · Neuropathology and Applied Neurobiology
73. Surface‐Modified Protein Microspheres Capture Amyloid‐β and Inhibit its Aggregation and Toxicity
    Michal Richman, Sarah Wilk, Natalia Skirtenko, Alex Perelman, Shai Rahimipour · 2011 · Chemistry - A European Journal
74. Involvement of Wiskott-Aldrich Syndrome Protein Family Verprolin-Homologous Protein (WAVE) and Rac1 in the Phagocytosis of Amyloid-β(1 – 42) in Rat Microglia
    Kitamura, Yoshihisa, Shibagaki, Keiichi, Takata, Kazuyuki, Tsuchiya, Daiju, Taniguchi, Takashi, Gebicke-Haerter, Peter J., Miki, Hiroaki, Takenawa, Tadaomi, Shimohama, Shun · 2003 · Journal of Pharmacological Sciences
75. Is there a future for vaccination as a treatment for Alzheimer's disease?
    P. L. McGeer · 2003 · Neurobiology of Aging
76. Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated β -Amyloid 1-42 Peptide
    Chad A. Dickey, David Morgan, Sagar B. Kudchodkar, David B. Weiner, Yun Bai, Chuanhai Cao, Marcia N. Gordon, Kenneth E. Ugen · 2001 · DNA and Cell Biology
77. The intricate role of CCL5/CCR5 axis in Alzheimer disease
    Weijiang Ma, Aihua Liu, Xinya Wu, Li Gao, Jingjing Chen, Hanxin Wu, Meixiao Liu, Yuxin Fan, Peng Li, Jiaru Yang et al. · 2023 · Journal of Neuropathology & Experimental Neurology
78. Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
    David H. Cribbs · 2010 · CNS & Neurological Disorders - Drug Targets
79. UDP Facilitates Microglial Phagocytosis Through P2Y6 Receptors
    Kazuhide Inoue · 2007 · Cell Adhesion & Migration
80. Regulation of Fcγ receptors and immunoglobulin G-mediated phagocytosis in mouse microglia
    Yi Quan, Thomas Möller, Jonathan R. Weinstein · 2009 · Neuroscience Letters
81. Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
    Youmei Wang, Tao Yan, Honghui Lu, Weiming Yin, Bin Lin, Weibin Fan, Xiaoli Zhang, Pedro Fernández-Fúnez · 2017 · Neurodegenerative Diseases
82. Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
    Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia et al. · 2020 · Immunology
83. Peli1 impairs microglial Aβ phagocytosis through promoting C/EBPβ degradation
    Jing Xu, Tao Yu, Enrica Caterina Pietronigro, Jia Yuan, Jessica Arioli, Yifei Pei, Xuan Luo, Jialin Ye, Gabriela Constantin, Chaoming Mao et al. · 2020 · PLoS Biology
84. Animal Models for Alzheimer’s Disease and Frontotemporal Dementia: A Perspective
    Jürgen Götz, Naeman N. Götz · 2009 · ASN NEURO
85. Effects of HNE‐modification induced by Aβ on neprilysin expression and activity in SH‐SY5Y cells
    Rui Wang, Suqing Wang, James S. Malter, Dengshun Wang · 2008 · Journal of Neurochemistry
86. AA-Amyloid is cleared by endogenous immunological mechanisms
    Sofia N. Nyström, Gunilla Torstensdotter Westermark · 2012 · Amyloid
87. Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models
    Thomas Wısnıewskı, Allal Boutajangout · 2009 · Brain Structure and Function
88. A$beta;1-15 is less immunogenic than A$beta;1-40/42 for intranasal immunization of wild-type mice but may be effective for ?boosting?
    Jodi F. Leverone · 2003 · Vaccine
89. Trichostatin A increases the levels of plasma gelsolin and amyloid beta-protein in a transgenic mouse model of Alzheimer's disease
    Wenzhong Yang, Abha Chauhan, Sangita P. Mehta, Pankaj D Mehta, Feng Gu, Ved P. S. Chauhan · 2014 · Life Sciences
90. Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease
    Maria Becker, Vered Lavie, Beka Solomon · 2007 · Proceedings of the National Academy of Sciences
91. Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer’s disease
    François Torreilles, Jacques Touchon · 2002 · Progress in Neurobiology
92. Novel approaches for immunotherapeutic intervention in Alzheimer's disease
    Vitaly Vasilevko, David H. Cribbs · 2006 · Neurochemistry International
93. HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigen-specific immune responses
    William J. Bowers, Michael A. Mastrangelo, Hilary A. Stanley, Ann E. Casey, Lawrence J. Milo, Howard J. Federoff · 2004 · Neurobiology of Aging
94. New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease
    Botond Penke, Mária Szűcs, Ferenc Bogár · 2023 · International Journal of Molecular Sciences
95. The immunology of B-1 cells: from development to aging
    Matheus Silvério Mattos, Sofie Vandendriessche, Ari Waisman, Pedro Elias Marques · 2024 · Immunity & Ageing
96. Plant-Based Nutraceutical Interventions against Cognitive Impairment and Dementia: Meta-Analytic Evidence of Efficacy of a Standardized Gingko biloba Extract
    Vincenzo Solfrizzi, Francesco Panza · 2014 · Journal of Alzheimer s Disease
97. APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice
    Pankiewicz, Joanna E, Baquero-Buitrago, Jairo, Sanchez, Sandrine, Lopez-Contreras, Jennifer, Kim, Jungsu, Sullivan, Patrick M., Holtzman, David M., Sadowski, Martin J. · 2017 · Molecular Neurodegeneration
98. Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid &amp;#946;-Derived Neurotoxins
    Lambert, Mary, Velasco, Pauline, Viola, Kirsten, Klein, William · 2009 · CNS &amp; Neurological Disorders - Drug Targets
99. Intracerebroventricular passive immunization with anti‐oligoAβ antibody in TgCRND8
    Chauhan, Neelima B. · 2007 · Journal of Neuroscience Research
100. Clinical immunologic approaches for the treatment of Alzheimer's disease
     Solomon, Beka · 2007 · Expert Opinion on Investigational Drugs